Hong Li

US Patent:

20130330367, Dec 12, 2013

Filed:

Aug 20, 2013

Appl. No.:

13/970918

Inventors:

Ge Liu - Cranbury NJ, US
Scott Umlauf - Cranbury NJ, US
Uma Kavita - Cranbury NJ, US
Hong Li - Cranbury NJ, US
Xiangyu Liu - Cranbury NJ, US
Bruce Weaver - Cranbury NJ, US
Lynda Tussey - Cranbury NJ, US

Assignee:

Vaxinnate Corporation - Cranbury NJ

International Classification:

C07K 14/195
C07K 14/005

US Classification:

4241851, 530350

Abstract:

The present invention relates to improved vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine and/or reduce reactogenicity to the vaccine when administered. In particular the vaccines and immunogenic compositions of the present invention relate to flagellin-antigen fusion proteins in which the spatial orientation of the flagellin to antigen and the charge distribution of the antigen is optimized to enhance immunogenicity and/or reduce reactogenicity. The present invention also relates to methods of evaluating the vaccines by measuring the relative expression of certain gene markers. Altered expression of the genes relative to flagellin control sample may indicate that the vaccine is suitable to stimulate an adaptive immune response to the antigen component in the subject with minimal side effects.

US Patent:

20140065177, Mar 6, 2014

Filed:

Jun 28, 2013

Appl. No.:

13/931028

Inventors:

Ge Liu - Cranbury NJ, US
Scott Umlauf - Cranbury NJ, US
Uma Kavita - Cranbury NJ, US
Hong Li - Cranbury NJ, US
Xiangyu Liu - Cranbury NJ, US
Bruce Weaver - Cranbury NJ, US
Lynda Tussey - Cranbury NJ, US

Assignee:

VaxInnate Corporation - Cranbury NJ

International Classification:

C07K 14/255
C07K 14/005

US Classification:

4241861, 530350

Abstract:

Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin.

US Patent:

20230114372, Apr 13, 2023

Filed:

Feb 5, 2021

Appl. No.:

17/911322

Inventors:

- Radnor PA, US
Joshua SUMOSKI - Somerville NJ, US
Jungmin OH - Somerville NJ, US
Hong LI - Plainsboro NJ, US
Jonathan FURA - Macungie PA, US
Nandu DEORKAR - Cedar Knolls NJ, US

Assignee:

AVANTOR PERFORMANCE MATERIALS, LLC - Radnor PA

International Classification:

C07K 1/22
C07K 17/06
C07K 16/00
C07K 14/705
B01D 15/20
B01D 15/36
B01D 15/32
B01D 15/38
B01J 20/32

Abstract:

The present invention relates to a novel polypeptide affinity ligand coupled to solid supports and affinity purification of IgG antibodies. The invention is comprised of (1) the design, generation, and purification of polypeptide ligands, (2) coupling of a polypeptide affinity ligand to a solid support matrix, (3) purification of IgG (polyclonal and monoclonal antibodies), and (4) cleaning and reuse of polypeptide supported solid matrix.

US Patent:

20150110827, Apr 23, 2015

Filed:

Dec 15, 2014

Appl. No.:

14/570682

Inventors:

- Cranbury NJ, US
Ge Liu - Cranbury NJ, US
Scott Umlauf - Cranbury NJ, US
Uma Kavita - Cranbury NJ, US
Hong Li - Cranbury NJ, US
Xiangyu Liu - Cranbury NJ, US
Bruce Weaver - Cranbury NJ, US
Lynda Tussey - Cranbury NJ, US

International Classification:

A61K 39/145
A61K 38/16
C12N 7/00

US Classification:

4241861

Abstract:

Compositions that include at least three fusion proteins comprising flagellin and influenza antigens. In embodiments, the influenza antigens can include influenza A and influenza B antigens. The composition can further include at least one adjuvant.

US Patent:

20140235836, Aug 21, 2014

Filed:

Apr 29, 2014

Appl. No.:

14/264745

Inventors:

- Cranbury NJ, US
Ge Liu - Cranbury NJ, US
Scott Umlauf - Cranbury NJ, US
Uma Kavita - Cranbury NJ, US
Hong Li - Cranbury NJ, US
Xiangyu Liu - Cranbury NJ, US
Bruce Weaver - Cranbury NJ, US
Lynda Tussey - Cranbury NJ, US

Assignee:

VaxInnate Corporation - Cranbury NJ

International Classification:

C07K 14/47
C07K 14/195

US Classification:

530396

Abstract:

The present invention relates to improved vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine and/or reduce reactogenicity to the vaccine when administered. In particular the vaccines and immunogenic compositions of the present invention relate to flagellin-antigen fusion proteins in which the spatial orientation of the flagellin to antigen and the charge distribution of the antigen is optimized to enhance immunogenicity and/or reduce reactogenicity and/or improve folding of the protein.